Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its Second Quarter Fiscal Year 2014 Financial Results
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m.
View HTML
Toggle Summary ImmunoGen, Inc. Reports Second Quarter Fiscal Year 2014 Financial Results and Provides Corporate Update
−Quarterly Conference Call Today at 8:00 am ET− Progress with all three wholly owned ImmunoGen compounds in clinical testing - IMGN853, IMGN529, IMGN289; decision made to discontinue IMGN901 development. Marked increase in partner activity in latter part of 2013, with multiple data presentations
View HTML
Toggle Summary ImmunoGen, Inc. Appoints Eric Guempel as Vice President of Product Strategy and Program Management
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (NASDAQ: IMGN), a biotechnology company that develops targeted anticancer therapies using its industry leading antibody-drug conjugate (ADC) technology, today announced the appointment of Eric Guempel as Vice President of Product Strategy and
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be
View HTML
Toggle Summary ImmunoGen, Inc. Appoints Ellie Harrison as Chief Human Resources Officer
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (NASDAQ: IMGN), a biotechnology company that develops targeted anticancer therapies using its antibody-drug conjugate (ADC) technology, today announced the appointment of Ellie Harrison as Vice President and Chief Human Resources Officer.
View HTML
Toggle Summary ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be
View HTML
Toggle Summary ImmunoGen, Inc. Announces Presentations by Company Scientists at Upcoming AACR Annual Meeting
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the presentations scheduled to be made by Company scientists at the American Association for
View HTML
Toggle Summary ImmunoGen, Inc. Announces First Clinical Findings with Refined Dosing Strategy for IMGN853
Initial Findings Show New Dosing Approach for IMGN853 Achieves Objective Data Presented at American Association for Cancer Research Annual Meeting WALTHAM, Mass. & SAN DIEGO --(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using
View HTML
Toggle Summary ImmunoGen, Inc. Announces Conference Call to Discuss its Third Quarter Fiscal Year 2014 Financial Results
WALTHAM, Mass. --(BUSINESS WIRE)-- ImmunoGen, Inc . (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m.
View HTML
Toggle Summary ImmunoGen, Inc. Reports Third Quarter Fiscal Year 2014 Financial Results and Provides Corporate Update −Quarterly Conference Call Today at 8:00 am ET−
Wholly owned product candidates - advancing, with expanding news flow expected. Kadcyla ® sales growing - launches in European Union starting. Beyond Kadcyla - encouraging initial clinical findings now reported with six other compounds in development through partnerships.
View HTML